Pioglitazone Is a Mild Carrier-Dependent Uncoupler of Oxidative Phosphorylation and a Modulator of Mitochondrial Permeability Transition

• Main Authors: Ekaterina S. Kharechkina (Author), Anna B. Nikiforova (Author), Konstantin N. Belosludtsev (Author), Tatyana I. Rokitskaya (Author), Yuri N. Antonenko (Author), Alexey G. Kruglov (Author)
• Format: Book
• Published: MDPI AG, 2021-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Pioglitazone (PIO) is an insulin-sensitizing antidiabetic drug, which normalizes glucose and lipid metabolism but may provoke heart and liver failure and chronic kidney diseases. Both therapeutic and adverse effects of PIO can be accomplished through mitochondrial targets. Here, we explored the capa...